Founded in 2004, the company operates within the medical consumables/disposables sector and specializes in the therapeutic areas of Anesthesia, Dialysis, Infusion Therapy and Urology. Farcomake’s main products are intravenous cannulas, blood lines, fistulas and IV Sets.
We have successfully reduced our ownership stake from 38% to 8.95% through a carefully structured management buyout (MBO) agreement. This move underscores our confidence in the management team’s ability to drive growth and value creation by taking a more substantial equity position in the company. By divesting a portion of our shares, we unlock capital for other strategic investments while maintaining a meaningful minority interest that aligns with our long-term vision.
Headquarters: Alexandria, Egypt
Investment Vintage Year: 2018
SEII’s Ownership Stake: 8.95%
www.farkomake.com